Trial · NCT03692052
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a Hemoglobin Response (HR) | AG-348 | 80.0 | 90% Confidence Interval 59.90 to 92.86 | percentage of participants | |
| Average Change From Baseline in Hb Concentrations From Week 12 to Week 24 | AG-348 | Baseline | 79.44 | Standard Deviation 13.690 | grams per liter (g/L) |
| Average Change From Baseline in Hb Concentrations From Week 12 to Week 24 | AG-348 | Average Change from Baseline: Week 12 to 24 | 13.01 | Standard Deviation 6.283 | grams per liter (g/L) |
| Percentage of Participants Achieving a Sustained Hb Response (sHR) | AG-348 | 65.0 | 90% Confidence Interval 44.20 to 82.27 | percentage of participants | |
| Percentage of Participants Achieving a Delayed Hb Response | AG-348 | 10.0 | 90% Confidence Interval 1.81 to 28.26 | percentage of participants | |
| Time to First ≥1.0 g/dL Increase in Hb Concentration | AG-348 | 4.54 | Standard Deviation 3.204 | weeks | |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 0.00 Hour, Day 1 | NA | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 0.50 Hour, Day 1 | NA | Geometric Coefficient of Variation NA | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 1 Hour, Day 1 | 785.2 | Geometric Coefficient of Variation 64.6 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 2 Hour, Day 1 | 694.5 | Geometric Coefficient of Variation 26.6 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 4 Hour, Day 1 | 369.2 | Geometric Coefficient of Variation 29.4 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 50 mg: 8 Hour, Day 1 | 128.9 | Geometric Coefficient of Variation 55.1 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 0.00 Hour, Week 12 | 39.39 | Geometric Coefficient of Variation 117.1 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 0.50 Hour, Week 12 | 1030 | Geometric Coefficient of Variation 137.7 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 1 Hour, Week 12 | 1442 | Geometric Coefficient of Variation 30.6 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 2 Hour, Week 12 | 740.1 | Geometric Coefficient of Variation 76.3 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 4 Hour, Week 12 | 302.8 | Geometric Coefficient of Variation 75.2 | nanograms per milliliter (ng/mL) |
| Drug Concentrations Over Time for AG-348 | AG-348 | AG-348 100 mg: 8 Hour, Week 12 | 77.35 | Geometric Coefficient of Variation 48.2 | nanograms per milliliter (ng/mL) |
| AUC0-8h: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours of AG-348 | AG-348 | AG-348 50 mg: Day 1 | 3083.3 | Geometric Coefficient of Variation 25.6 | nanograms*hour per milliliter (ng*h/mL) |
| AUC0-8h: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours of AG-348 | AG-348 | AG-348 100 mg: Week 12 | 3384.4 | Geometric Coefficient of Variation 65.7 | nanograms*hour per milliliter (ng*h/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03692052/results